We are excited to engage with the latest developments in hematology and to present our abstracts, which highlight innovative trial strategies and insights with the potential to transform treatment paradigms for newly diagnosed multiple myeloma patients.
Join us to explore our poster presentations, where we will share how we are investigating the safety and efficacy of some of the most promising novel therapies in the field today. Our experts will be on the ground alongside some of Europe’s most prominent Key Opinion Leaders, discussing some of the most effective methodologies that are helping bring us closer to delivering new.
Every year, over 1.24 million people are affected by blood cancer. At Veeda Lifesciences, we are deeply committed to supporting the hematology community in building a future where innovation means more time, more milestones, and more hope for patients.
Every trial we manage and every insight we contribute are driven by our mission to accelerate progress and improve the lives of patients battling hematological malignancies.